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 In medical and surgical practice, oliguria 
is usually seen as an ominous sign. Based 
on the need to eliminate at least 300 
mosmol / d in maximally concentrated 
urine (1200 mosmol / kg), oliguria is clas-
sically defi ned as a diuresis of less than 
400  ml / d (15  ml / h, 0.2 – 0.3  ml / kg / h). 1 In 
practice, oliguria is usually defined as 
d iuresis less than 0.5  ml / kg / h, especially 
in the perioperative period. 
 In a recent study, 2 Bouchard and 
collaborators showed the implications of 
fl uid overload, emphasizing the need to 
weigh patients daily and to collect accu-
rate intake-and-output data. Now, the 
same group of authors (Macedo  et al. , 3 
this issue) delves into hour-to-hour urine 
collections to answer two questions: (1) is 
oliguria a biomarker associated with 
important outcomes, such as acute kidney 
injury (AKI) and increased morbidity and 
mortality, and (2) will more acc urate 
measures of diuresis permit earlier 
AKI diagnosis? 
 Analysis was performed in a cohort of 
317 critically ill surgical patients from a 
prospective observational study on AKI. 
After screening on intensive care unit 
admission, all patients were included unless 
they had AKI by Acute Kidney Injury Net-
work (AKIN) criteria 4 or serum creatinine 
(SCr) greater than 177   mol / l for 3 days or 
less, had preexisting chronic kidney disease 
stage 5, were on chronic dialysis, or had a 
functioning renal transplant, liver cirrhosis, 
or severe anemia. 
 Data were collected between intensive 
care unit admission and discharge; admis-
sion SCr was considered the reference 
value. Daily and cumulative fl uid balance 
was computed, but detailed fl uid or di uretic 
administration was not recorded. Overall, 
the authors showed that the addition of 
the oliguria criterion was associated with 
increased patient morbidity and mortality, 
increased the incidence, and provided 
earlier diagnosis of AKI. 
 Analysis of the data showed poor sensi-
tivity and positive predictive value, which 
worsened as the oliguric interval length-
ened from 6 to 24  h: as a screening test, 
oliguria is a poor marker. Conversely, spe-
cifi city and negative predictive value were 
high when the more strict measures of 
oliguria (diuresis   <  0.5  ml / kg / h every hour 
for 6  h) were used: when patients show 
persistent, consistent oliguria for 6 hours 
or more, signifi cant renal injury is likely. 
This key observation introduces the 
concept that urine output data can be 
measured in 6-h blocks without loss 
of specifi city. Th is study also introduces 
the original concept of type A and type B 
oliguria (with and without concomitant 
increase in SCr, respectively), which 
in this study are independent of diuretic 
use. These constructs may facilitate 
future studies distinguishing prerenal 
from established AKI. 
 Because it is not unicausal, one can 
hardly expect oliguria to be a highly specifi c 
or sensitive sole marker of parenchymal 
ischemic injury. Multiple mechanisms 5 can 
potentially cause oliguria in this context 
( Figure 1 ), including overall reduction and 
regional intrarenal redistribution of blood 
fl ow; glomerular injury or altered intra-
glomerular hemodynamics; impaired tissue 
oxygenation causing preferential ischemia 
to the S 3 segment of the proximal convo-
luted tubule and the thick ascending loop 
of Henle; loss of osmolar gradient, intersti-
tial edema, or infl ammation; and tubular or 
lower urinary tract obstruction. Th e paper 
by Macedo  et al. 3 confi rms that oliguria is 
a marker, but establishing the mechanism 
will require much additional study. 
 Regardless of the mechanism, this paper 
shows that AKI diagnosis made on the basis 
of oliguria has survival implications. Mor-
tality is higher both for patients with oligu-
ria and elevated creatinine (type A) and for 
patients with isolated oliguria (type B) 
when compared with non-oliguric AKI or 
non-AKI patients. The increased area 
under the curve for mortality when the 
urine output criterion is added to the SCr 
criterion is important and contradicts pre-
vious studies. 6,7 Furthermore, these results 
improve on the fi ndings of Cruz  et al. , 8 who 
found a marginal independent mortality 
prediction on the basis of oliguria alone. 
The association of increasing mortality 
with longer-lasting or recurrent oliguria 
suggests the presence of a dose – eff ect rela-
tionship between the severity of renal 
injury and mortality. 
 As Macedo  et al. 3 discuss, the apparently 
earlier detection of AKI by oliguria than by 
SCr may be caused by the unavailability of 
every-12-hour data on SCr. Th erefore, if we 
intend to achieve earlier AKI diagnosis, 
daily SCr measurements are not good 
enough. Undoubtedly, the same will be true 
for the newer biomarkers currently being 
developed. Just as we have accepted the 
need to measure troponin repeatedly at 
much shorter intervals to diagnose acute 
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myocardial ischemia, there should be no 
diffi  culty for the medical community in 
accepting this premise. 
 Similarly, if oliguria will be used for ear-
lier, accurate diagnosis of AKI, 12- or 
24-h intervals are not acceptable: the 
marker is specifi c when oliguria is consist-
ently low, hour to hour over a 6-h period. 
Macedo  et al. 3 show that the gains in sen-
sitivity are associated with clinically sig-
nifi cant increases in morbidity (need for 
renal replacement therapy) and mortality, 
demanding lesser complacency with epi-
sodes of discontinuous oliguria over 6-h 
intervals. If diuresis decreases transiently, 
this study says, pay attention to the patient; 
ascertain whether the oliguria, even if not 
yet accompanied by an increase in SCr, is 
due to reversible, addressable reasons. 
Timely correction of volume contraction 
or hemodynamic instability is simple, may 
avoid progression to more ominous per-
sistent oliguria, and is probably eff ective. 
Th e study by Macedo  et al. 3 emphasizes 
that, very probably, early thorough evalu-
ation of the clinical situation will lead to 
timely changes in patient management 
resulting in avoidance of established AKI. 
We have achieved little in our eff orts to 
decrease the catastrophic morbidity and 
mortality of established AKI: we need to 
focus on early avoidance of the problem. 
Th e issue that clouds such important fi nd-
ings is that, from the data provided, it is 
unclear  ‘ what else is going on with ’ these 
patients and what is the relationship 
between oliguria, fl uid status, and treat-
ment (especially diuretics). 
 Fortunately, the installation of increas-
ingly accurate data collection systems in 
the intensive care unit, and the possibility 
of automated analysis of variables such as 
oliguria and its correlation with myriad 
other variables, will increasingly allow 
recognition of the problem at a much ear-
lier phase, when intervention is associated 
with the greatest benefi t at a lesser cost. 
For sure, such possibilities will permit us 
to recognize paradigms we cannot even 
envision at this time. 
 Predictably, patients with more severe 
comorbidities and more severe acute dis-
ease develop higher-stage AKI by AKIN 
criteria (progressing from 6-h oliguria to 
AKIN stage 3). Not surprisingly, patients 
fulfilling oliguria and SCr criteria are 
sicker. Conversely, the surprisingly low 
mortality of the sample (5.6 % overall, 
1.3 % non-AKI and 9.5 % AKI) makes the 
general application of these fi ndings more 
diffi  cult, when one considers the usually 
much higher mortalities seen among crit-
ically ill surgical patients with multiple 
organ dysfunctions. The exclusion of 
patients with AKI on admission probably 
infl uences the results. 
 It appears that non-oliguric patients with 
AKI (defi ned by SCr) and oliguric patients 
without an increase in SCr are very similar 
in their comorbidities and severity of acute 
disease, and few evolve to AKIN stage 3. 
Moreover, when defi ned by oliguria, AKIN 
stages 1 and 2 are not associated with 
increased mortality in this population 
except when the oliguria lasts more than 24 
hours (AKIN stage 3), and by then, very 
few patients are left  without an increase in 
SCr. Th e question arises of whether at least 
some of the oliguric patients without an 
increase in SCr actually do have AKI, or 
whether they are oliguric for some other 
reason (for example, volume contraction 
or congestive heart failure). Th e question 
has important implications because such 
situations have very disparate eff ects on 
SCr concentration, 9 the former increasing 
and the latter diluting SCr, as recently 
shown by this same group of authors. 10 In 
the absence of concurrent data on fl uid sta-
tus and medications (especially diuretics), 
it is diffi  cult to interpret the actual meaning 
of isolated oliguria. Conversely, the dem-
onstration by multivariable analysis that 
oliguric AKI is signifi cantly and independ-
ently associated with greater mortality 
when controlled by the degree of fluid 
overload lends support to the relevance of 
the identifi cation of AKI by this criterion. 
 Similar concerns apply to the use of the 
need for renal replacement therapy as an 
end point. In the absence of clear predefi ned 
timing and starting criteria, heterogeneity 
in the decision-making process increases 
the risk of signifi cant confounding. 
 Th e fi ndings in the paper by Macedo  et al. 3 
show that oliguria is more ominous than we 
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 Figure 1  |  Mechanisms of oliguria and acute kidney injury. Multiple mechanisms can 
potentially cause oliguria in the acutely injured kidney. Regional intrarenal differences in blood 
flow and redistribution; glomerular injury or altered intraglomerular hemodynamics; impaired 
tissue oxygenation causing preferential ischemia to the S 3 segment of the proximal convoluted 
tubule and the oxygen-avid thick ascending loop of Henle; loss of osmolar gradient, interstitial 
edema, or inflammation; and tubular or lower urinary tract obstruction can precipitate oliguria. 
CCD and MCD, cortical and medullary collecting ducts; Osm, osmolality; p t O 2 , tissue partial 
pressure of oxygen; Q B , renal blood flow; S 1 – S 3 , segments of the proximal convoluted tubule; 
TALH, thick ascending loop of Henle. 
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previously thought: it is an important early 
biomarker in its own right. Now we will have 
to work harder: oliguria should be seen in the 
context of early and frequent measurement 
of known and upcoming biomarkers, and in 
relationship with the overall fl uid status of 
the patient. Enriched with that information, 
we must continue to devise novel strategies 
of early AKI management. 
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 Hematologic malignancies have long been 
linked with glomerular disorders, and the 
list of such associations is continually 
expanding ( Table 1 ), although the patho-
genic mechanisms underlying a number of 
these glomerular lesions remain unclear. 
Th e most well-recognized and well-estab-
lished associations between hematologic 
and glomerular disorders are those involv-
ing plasma-cell dyscrasias, in which the 
monoclonal paraprotein or a product 
derived from it is deposited in the glomer-
uli, resulting initially in proteinuria and 
later, with increasing deposition of the 
abnormal protein, in renal insuffi  ciency. 
The spectrum of monoclonal immuno-
globulin deposition disease (MIDD) has 
been reviewed, 1 and our understanding of 
the amyloido genic properties of certain 
light chains is increasing. 2 Of course, renal 
involvement in MIDD and AL amyloidosis 
is not limited to glomeruli, although their 
progression often involves worsening 
glomerular pathology. Immunotactoid 
glomerulopathy, a rare lesion characterized 
by deposits within glomerular capillaries 
and mesangial areas that have a microtubu-
lar structure by electron microscopy, has 
emerged as another form of glomerular 
deposition disease associated with hemato-
logic neoplasms. Glomerular deposits in 
immunotactoid glomerulopathy are fre-
quently monoclonal, although the under-
lying hematologic disease is most oft en a 
low-grade B-cell neoplasm rather than a 
plasma-cell dyscrasia. This frequent 
association with B-cell neoplasms and the 
presence of monoclonal IgG within the 
glomerular deposits represent features that 
distinguish immunotactoid glomerulopa-
thy from the morphologically related lesion 
of fi brillary glomerulonephritis, which is 
only rarely associated with hematologic 
neoplasms and typically has polyclonal 
glomerular IgG deposits. 3 
 Deposition of monoclonal proteins in the 
context of hematologic neoplasms may also 
produce a pattern of proliferative glomeru-
lonephritis (GN) that must be distinguished 
from type I membranoproliferative GN 
(MPGN) and other forms of proliferative 
GN ( Table 1 ). Cryoglobulinemic GN due 
to monoclonal, type I cryoglobulins is rare 
but has a morphologic pattern similar to 
that of the more commonly seen cryoglob-
ulinemic GN with type III cryoglobulins, 
usually related to hepatitis C. 4 Unlike type 
I cryoglobulinemic GN, the more recently 
described proliferative GN with mono-
clonal IgG deposits is only infrequently 
associated with an underlying lymphoma 
or leukemia and is oft en seen in the absence 
of a detectable serum or urine paraprotein. 
However, this latter form of GN typically 
has an MPGN-type pattern, albeit without 
the intracapillary pseudothrombi and 
annular substructure of the deposits oft en 
seen in cryoglobulinemic GN. 5 It should 
also be remembered that intermediate- and 
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with hematopoietic neoplasms: 
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 Once thought to be limited mainly to lesions involving deposition of 
monoclonal paraproteins, glomerular diseases associated with 
hematologic neoplasms now include forms in which manifestations are 
probably mediated through cytokines or chemokines. Said  et al. 
studied one such lesion, myeloproliferative neoplasm-related 
glomerulopathy, and found it to be a late complication of these neoplasms, 
with a generally poor renal outcome. Whether earlier recognition of 
glomerular diseases associated with hematopoietic neoplasms can result 
in more effective treatment remains an important question. 
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